

Delivering integrated, efficient and innovative drug discovery and development solutions
We have delivered 11 pre-clinical drug candidates in 5 years including SCY-635, our anti-HCV clinical compound from our proprietary cyclophilin inhibitor technology platform.
Our contract service business includes:
SCYNEXIS has built a proprietary pipeline based upon our cyclophilin inhibition technology program.
SCYNEXIS has assembled a world-class, fully-integrated drug discovery and development team. SCYNEXIS delivers drugs.
SCYNEXIS advances anti-parasitic compounds for Animal, Human and Public Health indications.